TAILIN BIOTECH(SZ:300813) Xin Lang Cai Jing·2025-10-27 01:20Group 1 - The core point of the news is that Tailin Bio (300813.SZ) reported its Q3 2025 results, revealing a total of 7 institutional investors holding shares, which amounts to 9.9005 million shares or 8.17% of the total share capital, with a decline of 1.10 percentage points compared to the previous quarter [1] - Institutional investors include Qingdao Gaode Investment Partnership, Zhejiang Tailin Biotechnology Co., Ltd. - 2025 Employee Stock Ownership Plan, and UBS AG among others, indicating a diverse range of institutional interest [1] - The report also mentions that 23 public funds were not disclosed in this period compared to the previous quarter, including notable funds such as NuAn Duo Strategy Mixed A and China Europe CSI 300 Index Quantitative Enhancement A [1] Group 2 - From the foreign investment perspective, there was one new foreign institution disclosed this quarter, which is CITIC Securities Asset Management (Hong Kong) Co., Ltd. - Client Funds [2] - The report indicates that several foreign institutions, including BARCLAYS BANK PLC and Goldman Sachs, were not disclosed in this period compared to the previous quarter, suggesting a potential shift in foreign investment interest [2]